Divislab Revenue History — Quarter by Quarter

Divislab's revenue moved from ₹2,197 Cr in Q1 FY25 to ₹2,692 Cr in Q3 FY26, a 22.5% change over 3 quarters. The table keeps each quarter linked back to the underlying earnings page.

Revenue by Quarter

Quarter	Revenue (₹ Cr)	YoY Change
Q3 FY26	₹2,692 Cr	+12.1%
Q2 FY26	₹2,860 Cr	+17%
Q1 FY25	₹2,197 Cr	+18%

What management said about revenue

Q3 FY26 · Three dedicated CS projects to commercialize by Q3-Q4 CY2027

Three custom synthesis molecules currently in validation/regulatory approval stages are expected to start commercial volumes in the second half of calendar year 2027.

Q3 FY26 · Double-digit revenue growth trajectory maintained

Management reiterated expectation of double-digit constant currency growth, supported by a balanced pipeline across patent phases.

Q2 FY26 · Three major CS projects to commercialize in 1-2 years

Three dedicated custom synthesis projects are at various stages of validation/construction and are expected to contribute revenue within 1-2 years, subject to regulatory approvals.

Q2 FY26 · Constant currency revenue growth ~10.8% for H2

Management expects constant currency revenue growth for the second half to be similar to H1's 10.79%.

Q1 FY26 · Three Major Dedicated Projects with Long-Term Contracts

Three custom synthesis projects are underway with long-term supply commitments, expected to commercialize over the next 12-24 months.

Q1 FY26 · Peptide Capacity Commercialization in 12-14 Months

Solid-phase peptide synthesis capacity is expected to commercialize within 12-14 months, subject to regulatory approvals and customer timelines.

Q4 FY25 · Double-digit revenue growth in FY26

Management expects overall revenue to grow at a double-digit rate in FY26, driven by custom synthesis and generics.

Q4 FY25 · New CS contracts commercialization by late 2026/early 2027

The two long-term custom synthesis contracts announced are expected to start commercial production around Q3/Q4 2026 or early 2027, subject to regulatory approvals.

Q3 FY25 · Double-digit revenue growth target

Management targets double-digit revenue growth on a yearly basis, driven by custom synthesis and generics.

Q3 FY25 · Generics and custom synthesis to be 50-50%

The company aims for a balanced revenue mix of 50% generics and 50% custom synthesis over time.

Q2 FY25 · Contrast media volume growth of 20-30% YoY

Management expects year-on-year volume increase of 20-30% in contrast media, driven by long-term contracts and new qualifications.

Q2 FY25 · New generic launches from 2026 onwards

Multiple generic products are advancing towards customer qualifications and regulatory approvals, with revenue contributions expected from 2026.